• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $8,635 Mln
  • Price to Earnings Ratio price-to-earning 96.58
  • 12 Month Earnings monthly-earning $37 Mln

Penumbra Inc. (PEN) Share Price

$217.45

As on 12-Apr-2024 16:10 EDT

up-down-arrow $-5.01-2.25%

  • Prev Close info

    $222.46

  • Day's Openinfo

    $220.09

  • Today's Highinfo

    $222.31

  • Today's Lowinfo

    $216.78

  • Today's Volumeinfo

    171,281

  • 52 Week rangeinfo

    $180.93 - 348.67

Please wait...

Penumbra Inc. (PEN) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Penumbra (PEN)
-13.55 -10.00 -15.77 -24.14 -7.19 9.03 --
S&P BSE Sensex
2.77 1.01 3.52 23.42 14.40 13.97 12.62
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 12-Apr-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Penumbra (PEN)
13.07 -22.57 64.18 6.53 34.43 29.68 47.49
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Penumbra Inc. (PEN) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Penumbra Inc. (PEN)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Penumbra Inc. (PEN)

        Co-Founder, Chairman, President & CEO

        Mr. Adam Elsesser

        Co-Founder & Director

        Dr. Arani Bose M.D.

        Headquarters

        Alameda, CA

        FAQs for Penumbra Inc. (PEN)

        The total asset value of Penumbra Inc. (PEN) stood at $ 1,556 Mln as on 31-Dec-23

        The share price of Penumbra Inc. (PEN) is $217.45 (NYSE) as of 12-Apr-2024 16:10 EDT. Penumbra Inc. (PEN) has given a return of -7.19% in the last 3 years.

        Penumbra Inc. (PEN) has a market capitalisation of $ 8,635 Mln as on 11-Apr-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Penumbra Inc. (PEN) is 7.26 times as on 11-Apr-2024, a 1.38% premium to its peers’ median range of 3.05 times.

        The P/E (price to earnings) ratio of Penumbra Inc. (PEN) is 96.58 times as on 11-Apr-2024.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Penumbra Inc. (PEN) and enter the required number of quantities and click on buy to purchase the shares of Penumbra Inc. (PEN).

        Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California. Address: One Penumbra Place, Alameda, CA, United States, 94502

        The CEO & director of Mr. Adam Elsesser. is Penumbra Inc. (PEN), and CFO & Sr. VP is Dr. Arani Bose M.D..

        The promoters of Penumbra Inc. (PEN) have pledged 0% of the total equity as on Dec-23.

        Penumbra Inc. (PEN) Ratios
        Return on equity(%)
        8.35
        Return on capital employed(%)
        6.87
        Debt-to-equity ratio
        0.2
        Dividend yield(%)
        --

        Yes, TTM profit after tax of Penumbra Inc. (PEN) was $37 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $8,635.18 Mln
        • Revenue (TTM)revenue-information $1,058.52 Mln
        • Earnings (TTM) earning-information $36.74 Mln
        • Cash date-information $289.19 Mln
        • Total Debt info $234.34 Mln
        • Insider's Holding 3.82%
        • Liquidity liquidity High
        • 52 Week range week-range $180.93 - 348.67
        • Shares outstanding share-outstanding 38,703,700
        • 10 Years Aggregate:

          CFO: $44.61 Mln

          EBITDA: $247.81 Mln

          Net Profit: $151.46 Mln

        About The Company

        • IPO Date 18-Sep-2015
        • Co-Founder, Chairman, President & CEO Mr. Adam Elsesser
        • Co-Founder & Director Dr. Arani Bose M.D.
        • Listing key-listing NYSE: PEN
        • Country United States
        • Headquarters headquarters Alameda, CA
        • Website website https://www.penumbrainc.com
        • Business

          Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of...  thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California. Address: One Penumbra Place, Alameda, CA, United States, 94502  Read more

        share-fund-plan-icon